These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32989931)

  • 1. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
    Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
    J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
    Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
    Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort.
    Gamba A; Depascale R; Zanatta E; Ienna L; Cruciani C; Gatto M; Zen M; Doria A; Iaccarino L
    Clin Rheumatol; 2024 Oct; 43(10):3167-3174. PubMed ID: 39196499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies.
    Janardana R; Amin SN; Rajasekhar L; Pinto B; Kodishala C; Selvam S; Shobha V
    Rheumatology (Oxford); 2023 Mar; 62(3):1243-1247. PubMed ID: 35946502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.
    Couderc M; Gottenberg JE; Mariette X; Hachulla E; Sibilia J; Fain O; Hot A; Dougados M; Euller-Ziegler L; Bourgeois P; Larroche C; Tournadre A; Amoura Z; Mazières B; Arlet P; De Bandt M; Schaeverbeke T; Soubrier M
    Rheumatology (Oxford); 2011 Dec; 50(12):2283-9. PubMed ID: 22019807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
    Unger L; Kampf S; Lüthke K; Aringer M
    Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
    de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
    Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.
    Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C
    Front Immunol; 2022; 13():1051609. PubMed ID: 36578492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroid Monotherapy Is Usually Insufficient Treatment for Idiopathic Inflammatory Myopathy.
    Mathur T; Manadan AM; Thiagarajan S; Hota B; Block JA
    Am J Ther; 2015; 22(5):350-4. PubMed ID: 23797759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.
    Campochiaro C; Farina N; De Luca G; Batani V; Trignani G; Vignale D; Palmisano A; Matucci-Cerinic M; Dagna L
    Arthritis Res Ther; 2024 Apr; 26(1):79. PubMed ID: 38570792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series.
    Basnayake C; Cash K; Blumbergs P; Limaye V
    Clin Rheumatol; 2015 Feb; 34(2):371-7. PubMed ID: 24337692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for Inflammatory Myopathies in a Colombian Cohort.
    Santos VA; Aragón CC; Posso-Osorio I; Naranjo-Escobar J; Milisenda JC; Obando MA; Barrera T; Zamorano L; Hormaza-Jaramillo A
    J Clin Rheumatol; 2021 Sep; 27(6S):S232-S235. PubMed ID: 33337818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
    Muñoz-Beamud F; Isenberg DA
    Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study.
    Conticini E; d'Alessandro M; Grazzini S; Rizzo C; Fornaro M; Cameli P; Bennett D; Abbruzzese A; Camarda F; Lopalco G; Bergantini L; Falsetti P; Bargagli E; Iannone F; Guggino G; Chinoy H; Cantarini L; Frediani B
    Clin Exp Rheumatol; 2023 Mar; 41(2):285-290. PubMed ID: 36861742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
    Reis J; Aguiar F; Brito I
    Acta Reumatol Port; 2016; 41(1):45-55. PubMed ID: 27115107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy.
    Raghu P; Manadan AM; Schmukler J; Mathur T; Block JA
    Am J Ther; 2015; 22(4):244-7. PubMed ID: 25490616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
    Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
    J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
    Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
    Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of rituximab efficacy in treatment-naive and refractory inflammatory myopathies: experiences from a tertiary care centre.
    Manwatkar A; Naresh K; Mathew J; Nair AV; Goel R; Yadav B; Prakash JAJ; Das JK; Sivadasan A
    Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38814804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.